Completion report on merger, etc. (merger)

What happened

Completion Report on Merger, etc. 6.0 Cytogen Co., Ltd. Completion Report on Merger, etc. (Merger) To: The Governor of the Financial Supervisory Service October 1, 2026 Company name: Cytogen Co., Ltd. CEO: An Ji-hun Head office location: 4th floor (Units 3, 4), Bldg. B, 60 Gwacheon-daero 7na-gil, Gwacheon-si, Gyeonggi-do (Galhyeon-dong, Gwacheon Urban Hub) (Tel) 02-6925-1070 (Website) http://www.cytogenlab.com Preparer: (Title) Executive Director (Name) Jeong Yoon-young (Tel) 02-6925-1070

I. Schedule Category: Merger board resolution date; Date: 2026.07.29 (Wed); Note: not applicable Category: Record date setting announcement; Date: 2026.07.29 (Wed); Note: not applicable Category: Merger agreement date; Date: 2026.07.30 (Thu); Note: not applicable Category: Record date for determining shareholders; Date: 2026.08.13 (Thu); Note: record date for determining the rights-holding shareholders entitled to express objection to the small-scale merger Category: Small-scale merger announcement; Date: 2026.08.13 (Thu); Note: not applicable Category: Period for receiving notices of objection to the merger; Date: 2026.08.13 (Thu) ~ 2026.08.28 (Fri); Note: within two weeks of the merger announcement date Category: Board resolution date approving the merger; Date: 2026.08.31 (Mon); Note: board approval substitutes for a general shareholders' meeting Category: Creditor objection submission announcement; Date: 2026.08.31 (Mon); Note: not applicable Category: Creditor objection submission period; Date: 2026.08.31 (Mon) ~ 2026.09.30 (Wed); Note: announcement period of 1 month or more Category: Merger effective date; Date: 2026.10.01 (Thu); Note: not applicable Category: Board resolution date for the merger completion report; Date: 2026.10.01 (Thu); Note: substitutes for the merger completion report general meeting Category: Merger completion report announcement; Date: 2026.10.01 (Thu); Note: posted on the company's website Category: Expected merger registration date; Date: 2026.10.01 (Thu); Note: to proceed without delay after merger registration

II. Changes in equity holdings of the largest shareholder, etc. Cytogen Co., Ltd. holds 100% of the equity of GenomeCare Co., Ltd., and the company absorbs and merges with the dissolving company at a merger ratio of 1:0; no new shares will be issued by the merging company as a result of this merger. Accordingly, no new shares are issued through this merger, and there is no change in the equity holdings of the largest shareholder, etc.

III. Exercise of appraisal (stock purchase) rights Since this merger proceeds as a small-scale merger under Article 527-3 of the Commercial Act, appraisal rights are not granted. In addition, pursuant to Article 527-3 of the Commercial Act, notices of objection to the merger were received from August 13, 2026 to August 28, 2026; a total of 963 shareholders notified their objection to the merger, with the number of shares for which objection was expressed totaling 236,678 shares (1.02% of total issued shares).

IV. Matters concerning creditor protection The surviving company, Cytogen Co., Ltd., and the dissolving company, GenomeCare Co., Ltd., each issued a public notice for creditor objections on August 31, 2026. During the creditor objection submission period (August 31, 2026 ~ September 30, 2026), no creditor submitted an objection, and no decision was made to repay debts or provide substantial collateral in connection with this matter.

V. Status of related litigation As of the filing date of this report, no litigation that could affect the validity of this merger has been filed.

VI. Matters concerning allotment of new shares, etc. Cytogen Co., Ltd. holds 100% of the equity of GenomeCare Co., Ltd., and the company absorbs and merges with the dissolving company at a merger ratio of 1:0; no new shares will be issued by the merging company as a result of this merger.

VII. Summary financial information before and after the merger, etc. (unit: KRW) Category: Before merger - Cytogen Co., Ltd.; Before merger - GenomeCare Co., Ltd.; After merger - Cytogen Co., Ltd. Current assets: 26,524,289,556; 6,736,101,360; after merger: 33,260,390,916 Non-current assets: 19,164,456,947; 4,503,282,807; after merger: 19,267,180,931 Total assets: 45,688,746,503; 11,239,384,167; after merger: 52,527,571,847 Current liabilities: 2,479,230,114; 1,643,354,893; after merger: 4,122,585,007 Non-current liabilities: 16,017,022,958; 195,485,048; after merger: 16,212,508,006 Total liabilities: 18,496,253,072; 1,838,839,941; after merger: 20,335,093,013 Capital stock: 11,564,773,500; 2,200,000,000; after merger: 11,564,773,500 Share premium: 102,225,864,056; 2,971,287,627; after merger: 102,225,864,056 Retained earnings (accumulated deficit): (107,693,511,578); 3,894,664,024; after merger: (103,045,387,217) Other components of equity: 21,095,367,453; 334,592,575; after merger: 21,447,228,495 Total equity: 27,192,493,431; 9,400,544,226; after merger: 32,192,478,834 Total liabilities and equity: 45,688,746,503; 11,239,384,167; after merger: 52,527,571,847

- The summary financial information above was prepared based on figures as of June 30, 2026, and may differ from the financial information to be prepared as of the actual merger effective date (2026.10.01). - The summary statement of financial position above has not been audited (reviewed) by an external auditor and may change depending on the external auditor's audit (review).